ArticleTranslational lung cancer research2024
Effectiveness of artificial intelligence for detecting operable lung cancer on chest radiographs.
Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the importance of early diagnosis of lung cancer and wide availability of chest radiography, the detection of operable stage lung cancer on chest radiographs (CXRs) remains challenging. This study aimed to investigate the effectiveness of artificial intelligence (AI)-based CXR analysis for detecting operable lung cancers. Methods: Patients who underwent lung cancer surgery at two referral hospitals between March 2020 and February 2021 were retrospectively included in this study. Preoperative CXRs of the patients were analyzed using commercial AI-based lesion detection software, and the results of lesion location and types obtained using the software were reviewed by radiologists and pulmonologists, with computed tomography (CT) as a reference standard for determining nodule characteristics. Factors influencing AI detection of lung cancer on CXR were assessed using logistic regression analysis. Results: Among the 594 patients who underwent surgery for lung cancer (median age: 65 years, 51.3% male), the sensitivity of AI for detecting lung cancer on CXR was 57.7%, and it identified 86% of CXR-visible lung cancers. Detection rates of lung cancer by AI increased according to the disease stage: 42.5% for stage IA, 86.3% for stage IB, and 90.9% for stages II-III. The detection rate increased to over 60% from stage IA2 onwards when tumor size exceeded 1 cm. Regarding lesion type on CT, 8.3%, 46.8%, and 77.3% of non-solid, part-solid, and solid nodules, respectively, were detected by AI. Multivariable analysis showed that nodule location in the upper zone [odds ratio (OR) 2.78, P<0.001], peripheral region (OR 4.59, P<0.001), and solid lesion diameter (OR 1.20, P<0.001) were significantly associated with AI detection of lung cancer. Conclusions: AI could be an effective tool for detecting operable lung cancer on CXRs, particularly when lesions are larger and located in the upper and peripheral regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.